EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Allogeneic islet products for type 1 diabetes: Navigating nonclinical and manufacturing regulatory expectations

Chengyuan Press, Kevin D'Amour, Nicholas Mamrak, David Pepperl, Robert H Kutner, Diana M Colleluori, Melanie L Graham, Michael A Brehm, Nasir Hussain, Esther Latres, Marjana Marinac

Stem Cell Reports · 2026

DOI: 10.1016/j.stemcr.2026.102998 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Stem Cell Reports, 2026. Verfasst von Chengyuan Press und 10 weiteren Autor:innen. Beteiligte Einrichtung: Breakthrough T1D, New York, NY, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Islets of Langerhans Transplantation, Islets of Langerhans. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breakthrough T1D.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Next-generation allogeneic islet cell products-including stem cell (SC)-derived, gene-edited, and encapsulated islets-offer scalable and curative solutions to restore physiological glucose control in type 1 diabetes. The critical path to success for these complex therapies hinges on robust nonclinical pharmacology and toxicology evidence and rigorous, scalable, and well-controlled manufacturing. We discuss strategies for essential nonclinical data for First-in-Human trials, emphasizing SC-specific risks, question-specific model selection, stage-by-stage process characterization, and safety, identity, purity, and potency testing. This paper serves as a resource for developers, highlighting best practices and regulatory expectations to advance transformative T1D cell therapies from bench to clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Islets of Langerhans TransplantationIslets of LangerhansAnimalsHumansTransplantation, HomologousStem Cells

Stichwörter der Autor:innen

animal modelschemistryislet transplantationmanufacturing and controlsnonclinical studiesqualitystem cell therapytype 1 diabetesβ-cells

Autor:innen und Institutionen

  • Breakthrough T1D, New York, NY, USA.
  • Independent Consultant, Redwood City, CA, USA.
  • Biologics Consulting Group, Inc., Alexandria, VA, USA.
  • Preclinical Research Center, Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.
  • Program in Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
  • Breakthrough T1D, New York, NY, USA. Electronic address: mmarinac@breakthrought1d.org.

Förderung

  • Breakthrough T1D

Zitieren

APA

Press, C., D'Amour, K., Mamrak, N., Pepperl, D., Kutner, R. H., Colleluori, D. M., Graham, M. L., Brehm, M. A., Hussain, N., Latres, E., & Marinac, M. (2026). Allogeneic islet products for type 1 diabetes: Navigating nonclinical and manufacturing regulatory expectations. Stem Cell Reports. https://doi.org/10.1016/j.stemcr.2026.102998

Vancouver

Press C, D'Amour K, Mamrak N, Pepperl D, Kutner RH, Colleluori DM, et al. Allogeneic islet products for type 1 diabetes: Navigating nonclinical and manufacturing regulatory expectations. Stem Cell Reports. 2026. doi:10.1016/j.stemcr.2026.102998

BibTeX
@article{Press2026,
  author = {Press, Chengyuan and D'Amour, Kevin and Mamrak, Nicholas and Pepperl, David and Kutner, Robert H and Colleluori, Diana M and Graham, Melanie L and Brehm, Michael A and Hussain, Nasir and Latres, Esther and Marinac, Marjana},
  title = {Allogeneic islet products for type 1 diabetes: Navigating nonclinical and manufacturing regulatory expectations},
  journal = {Stem Cell Reports},
  year = {2026},
  doi = {10.1016/j.stemcr.2026.102998}
}
Kostenlos starten →